An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam
A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating Sustained Response in Subjects With HBeAg Positive Chronic Hepatitis B Receiving Therapy With Pegasys (Peginterferon Alfa-2a) in Vietnam
Sponsor: Hoffmann-La Roche
Terminated
Due to out-of-date design and non-compliance.
Other terminated trials from Hoffmann-La Roche
Listed as NCT01886300, this observational or N/A phase trial focuses on Hepatitis B, Chronic and remains terminated or withdrawn. Sponsored by Hoffmann-La Roche, it has been updated 7 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Jun 2018 — Jan 2021 [monthly]
Terminated
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Terminated NA
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .